Source

From GlobeNewswire

6 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.

Koil Energy Solutions, Inc.10h ago

KOIL Energy Announces Pricing of $5.6 Million Private Placement and Preliminary Third Quarter 2026 Financial Results

Preliminary Third Quarter Revenue Expected Between $9.4 Million and $10.0 Million, Representing Year-Over-Year Growth of Approximately 48% to 57%

XBiotech Inc.Oct 26, 2026

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Strive, Inc.Oct 26, 2026

Strive Announces $1.0 Billion SATS At-The-Market Program

Oruka Therapeutics, Inc.Oct 26, 2026

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A

Climb Bio, Inc.Oct 26, 2026

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data;…

ArriVent BioPharma, Inc.Oct 26, 2026

KOIL Energy Announces Pricing of $5.6 Million Private Placement and Preliminary Third Quarter 2026 Financial Results

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Strive Announces $1.0 Billion SATS At-The-Market Program

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026